SLC16A7 and neoplasm: There was no significant change in MCT2 protein expression between AR blockade (Degarelix) treated and untreated PCa tumours, suggesting that any AR signalling effects on specific SLC16A7/MCT2 isoforms do not impact on total MCT2 protein levels in the context of human PCa tumours.